|
- Johnson Johnson: Changing health for humanity
Johnson Johnson MedTech innovates at the intersection of biology and technology With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex diseases Healthcare areas include: Cardiovascular, Orthopaedics, Surgery and
- Explore careers at Johnson Johnson | Johnson Johnson Careers
Elevate your career with J J Discover global job opportunities to drive innovation, impact lives and grow in a supportive, mission-driven culture
- Johnson Johnson’s dual-targeting CAR T-cell therapy shows encouraging . . .
Johnson Johnson ’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19 CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose
- Contact us - Johnson Johnson
Get in touch with Johnson JohnsonDo not sell or share my personal information Limit the use of my sensitive personal information
- Media Center - Johnson Johnson
Read the latest press releases from Johnson Johnson, find our press contacts and see our latest social media posts
- Our history - Johnson Johnson
We believe good health is the foundation of vibrant lives, thriving communities and forward progress That’s why for 139 years, we have aimed to keep people well at every age and every stage of life Learn about our history
- Pipeline - Innovative Medicine pipeline | Johnson Johnson
Development pipeline Select programs in development, Phase 1 through Approval (removed after programs achieve approval in both US EU) Learn more
- Johnson Johnson Reports Q4 and Full-Year 2024 Results
NEW BRUNSWICK, N J -- (BUSINESS WIRE)-- Johnson Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024 "2024 was a transformative year for Johnson Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson “As a healthcare company
|
|
|